Evidence map›Paper›PMID 41133009›Full record

ArticleTranslational lung cancer research2025

Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study.

Beibei Liu, Danni Wang, Yujing Li, Fangfei Qian, Yanwei Zhang, Lele Zhang, Xinwei Wu, Xuemei Liu, Wenyan Ma, Wei Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Beibei Liu *Department of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Danni Wang *Department of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yujing Li *Department of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Fangfei QianDepartment of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yanwei ZhangDepartment of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Lele ZhangDepartment of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xinwei WuDepartment of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xuemei LiuDepartment of Radiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wenyan MaDepartment of Clinical Research Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wei ZhangDepartment of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Lvkan WengDepartment of Science and Education, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yuqing LouDepartment of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Rong LiDepartment of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As a rare tumor with poor prognosis, the first-line treatment strategy of advanced SMARCA4-deficient thoracic tumors is inconclusive. Although previous studies have shown immunotherapy to be effective, the efficacy and safety of different immune checkpoint inhibitors (ICIs) combination treatment strategies have not been explored in detail. This study aims to identify optimal immunotherapeutic combinations for this population. Methods: We collected the clinical and pathological information of 55 patients with SMARCA4-deficient non-small cell lung cancer (SMARCA4-deficient NSCLC) and SMARCA4-deficient undifferentiated tumor (SMARCA4-deficient UT), after which we evaluated and analyzed the survival status and clinicopathological characteristics of the patients. Results: Following statistical analysis, it was found that the patients were mainly male smokers with a mean age of 66 years (range, 46-81 years old). Histologically, NSCLC accounts for the majority (n=40, 72.7%). Survival analysis demonstrated that overall survival (OS) was significantly longer in patients who received first-line immunotherapy compared to those who did not receive immunotherapy for first line (21.67 Conclusions: The early use of ICI-based treatment may result in superior survival outcomes for these patients with SMARCA4-deficient thoracic tumors compared to other treatment modalities. Besides, ICIs combined with anti-angiogenesis therapy may be a potential first-line treatment.

Indexed as

anti-angiogenesisimmune checkpoint inhibitor (ICI)non-small cell lung cancer (NSCLC)SMARCA4undifferentiated tumor (UT)

Identifiers

PMID41133009
PMCPMC12541656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.